AANPCB Board Prep/Pharmacology
💊

Pharmacology

Mechanisms of action, prescribing guidelines, drug interactions, side effects, and therapeutic monitoring.

244 questions · AANPCB knowledge area

Practice Pharmacology Questions

Build a custom quiz and track your performance across AANPCB knowledge areas and process domains.

Build a Quiz

All 244 questions

1.
SSRI Mechanism of Action and Selection
beginnerSSRImechanism of actionmajor depressive disorder
→
2.
SSRI Discontinuation Syndrome Management
beginnerSSRI discontinuationparoxetinetaper
→
3.
Lithium Therapeutic Monitoring and Toxicity
intermediatelithiumtoxicityrenal function
→
4.
Clozapine ANC Monitoring Requirements
intermediateclozapineANC monitoringagranulocytosis
→
5.
Serotonin Syndrome Recognition and Diagnosis
intermediateserotonin syndrometramadolHunter criteria
→
6.
CYP450 Drug Interaction: Fluvoxamine and Clozapine
advancedCYP1A2fluvoxamineclozapine
→
7.
Lamotrigine Titration and Stevens-Johnson Risk
intermediatelamotrigineStevens-Johnson syndromebipolar depression
→
8.
MAOI Dietary Restrictions and Hypertensive Crisis
intermediateMAOItyraminehypertensive crisis
→
9.
Benzodiazepine Equivalency and Taper Strategy
advancedbenzodiazepine taperdiazepam equivalencyalprazolam
→
10.
Antipsychotic Metabolic Monitoring Guidelines
beginnermetabolic monitoringolanzapineantipsychotic
→
11.
Stimulant Prescribing in ADHD with Cardiac History
advancedstimulant prescribingADHDcardiac screening
→
12.
First-Line SSRI Selection for MDD
beginnerMDDSSRIpharmacotherapy
→
13.
Augmentation Strategies for Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationaripiprazole
→
14.
First-Line Pharmacotherapy for Acute Mania
intermediatebipolar disorderacute manialithium
→
15.
Medication Selection for Comorbid Anxiety and Depression
beginnercomorbidityGADMDD
→
16.
Clozapine Indication in Treatment-Resistant Schizophrenia
advancedclozapinetreatment-resistant schizophreniaANC monitoring
→
17.
Antidepressant Use in Pregnancy: SSRI Safety and Risk-Benefit Analysis
advancedpregnancySSRIsertraline
→
18.
Geriatric Psychopharmacology and the AGS Beers Criteria
intermediateBeers Criteriageriatricanticholinergic
→
19.
Pediatric Black Box Warning: Antidepressants and Suicidality Risk
beginnerblack box warningpediatric depressionfluoxetine
→
20.
Venlafaxine Selection for Comorbid Depression and Chronic Pain
intermediatevenlafaxineSNRIfibromyalgia
→
21.
Quetiapine Off-Label Use for Insomnia: Risks and Appropriateness
beginnerquetiapineoff-label prescribinginsomnia
→
22.
Naltrexone vs Acamprosate for Alcohol Use Disorder
intermediatenaltrexoneacamprosatealcohol use disorder
→
23.
Prazosin for PTSD-Related Nightmares
beginnerprazosinPTSDnightmares
→
24.
Antipsychotic-Induced Akathisia Recognition and Management
intermediateakathisiaextrapyramidal symptomsaripiprazole
→
25.
Trazodone Mechanism and Appropriate Use for Insomnia
beginnertrazodoneSARIinsomnia
→
26.
Valproate Teratogenicity and Pregnancy Counseling
advancedvalproateteratogenicitypregnancy
→
27.
Long-Acting Injectable Antipsychotics: Indications and Advantages
advancedlong-acting injectableantipsychoticschizophrenia
→
28.
Buspirone Mechanism and Clinical Niche
beginnerbuspirone5-HT1A partial agonistgeneralized anxiety disorder
→
29.
Gabapentin Misuse Potential and Prescribing Considerations
intermediategabapentinmisuse potentialopioid use disorder
→
30.
Switching Antidepressants: Washout Periods and Cross-Titration
intermediateantidepressant switchingwashout periodfluoxetine
→
31.
Methylphenidate vs Amphetamine: Pharmacological Differences
advancedmethylphenidateamphetamineADHD
→
32.
Bupropion NDRI Mechanism and Dual Indications
beginnerbupropionNDRIsmoking cessation
→
33.
Trazodone Alpha-1 Blockade: Orthostatic Hypotension and Priapism
intermediatetrazodonealpha-1 antagonismorthostatic hypotension
→
34.
Mirtazapine Receptor Profile, Weight Gain, and Sedation
intermediatemirtazapineNaSSAH1 antagonism
→
35.
Venlafaxine Serotonin vs Norepinephrine Dose Threshold
intermediatevenlafaxineSNRIdose-dependent
→
36.
Duloxetine for Comorbid Depression and Chronic Pain
beginnerduloxetineSNRIdiabetic neuropathy
→
37.
Clonidine vs Guanfacine for ADHD: Alpha-2 Agonist Comparison
intermediateclonidineguanfacinealpha-2 agonist
→
38.
Atomoxetine Mechanism and Monitoring for ADHD
intermediateatomoxetinenorepinephrine reuptake inhibitorADHD
→
39.
Naltrexone Oral vs Injectable for AUD and OUD
advancednaltrexoneVivitrolinjectable
→
40.
Buspirone Delayed Onset of Action and Patient Education
beginnerbuspironeonset of actionpatient education
→
41.
Prazosin Titration and Blood Pressure Monitoring for PTSD Nightmares
intermediateprazosinPTSD nightmarestitration
→
42.
Gabapentin vs Pregabalin: Pharmacokinetic Differences
intermediategabapentinpregabalinpharmacokinetics
→
43.
Hydroxyzine vs Diphenhydramine for Anxiety
beginnerhydroxyzinediphenhydramineantihistamine
→
44.
Propranolol for Performance Anxiety
beginnerpropranololbeta-blockerperformance anxiety
→
45.
Valproate Laboratory Monitoring and Hepatotoxicity Risk
intermediatevalproatelaboratory monitoringhepatotoxicity
→
46.
Carbamazepine CYP3A4 Autoinduction and Drug Interactions
advancedcarbamazepineCYP3A4 inductionoral contraceptives
→
47.
Fluvoxamine CYP1A2 Inhibition: Caffeine and Theophylline
advancedfluvoxamineCYP1A2caffeine
→
48.
Aripiprazole Partial Dopamine Agonism Mechanism
intermediatearipiprazolepartial agonistdopamine stabilizer
→
49.
Quetiapine Dose-Dependent Receptor Binding
advancedquetiapinedose-dependent bindingreceptor hierarchy
→
50.
Long-Acting Injectable Antipsychotics: Oral Overlap and Loading Strategy
advancedpaliperidone palmitatelong-acting injectableloading dose
→
51.
Augment vs. Switch: Antidepressant Partial Response
intermediateaugmentationswitchingpartial response
→
52.
Treatment Planning for Depression with Alcohol Use Disorder
intermediatedual diagnosisalcohol use disorderMDD
→
53.
Cultural Considerations in Medication Selection
intermediatecultural considerationspharmacogenomicsCYP2C19
→
54.
Tapering Plan for Long-Term Benzodiazepine Use
advancedbenzodiazepine taperingclonazepamdiazepam
→
55.
Antidepressant Prescribing During Breastfeeding
intermediatebreastfeedingsertralinepostpartum depression
→
56.
Opioid Use Disorder in Pregnancy and Neonatal Abstinence Syndrome
intermediateOUDpregnancybuprenorphine
→
57.
Aripiprazole Cross-Titration: Worsening Symptoms During Switch from Full Antagonist
advancedaripiprazolepartial agonismcross-titration
→
58.
Lurasidone Non-Response Troubleshooting: Inadequate Caloric Intake
intermediatelurasidoneclinical troubleshootingbioavailability
→
59.
Gabapentin vs Pregabalin: Abuse Potential and Scheduling Differences
intermediategabapentinpregabalinabuse potential
→
60.
Hydroxyzine for Anxiety: Mechanism and Clinical Limitations
beginnerhydroxyzineH1 antagonistgeneralized anxiety disorder
→
61.
Quetiapine 25 mg: Sedative-Hypnotic, Not Antipsychotic
intermediatequetiapinedose-dependent pharmacologyclinical application
→
62.
Buspirone CYP3A4 Drug Interaction with Azole Antifungal
intermediatebuspironeCYP3A4drug interaction
→
63.
Venlafaxine Discontinuation Syndrome: Recognition and Management
intermediatevenlafaxinediscontinuation syndromehalf-life
→
64.
Duloxetine Analgesic Mechanism: Descending Pain Inhibition via Norepinephrine
intermediateduloxetineanalgesic mechanismdescending pain pathways
→
65.
Carbamazepine Autoinduction and Declining Serum Levels
advancedcarbamazepineautoinductionCYP3A4
→
66.
Propranolol for Performance Anxiety: Mechanism and Asthma Contraindication
beginnerpropranololperformance anxietybeta-blocker
→
67.
Stimulant Class Switch After Methylphenidate Failure: Clinical Rationale
intermediatemethylphenidateamphetamineADHD
→
68.
SSRI Selection for OCD in a Patient on Clozapine: Managing the CYP1A2 Interaction
advancedclozapinefluvoxamineCYP1A2
→
69.
Ramelteon: Melatonin Receptor Agonism and Absence of Abuse Potential
intermediateramelteonmelatonin receptor agonistinsomnia
→
70.
Dextromethorphan-Bupropion (Auvelity): NMDA Mechanism for Depression
advanceddextromethorphan-bupropionAuvelityNMDA antagonist
→
71.
Pimozide QTc Prolongation and CYP2D6 Inhibitor Contraindication
advancedpimozideQTc prolongationCYP2D6
→
72.
Naloxone Precipitated Withdrawal: Mechanism and Clinical Presentation
advancednaloxoneprecipitated withdrawalmu-opioid receptor
→
73.
SSRI Discontinuation Syndrome and Tapering Principles
intermediateSSRI discontinuation syndromeparoxetinetapering
→
74.
Augmentation Strategies for Treatment-Resistant OCD
advancedtreatment-resistant OCDaugmentationrisperidone
→
75.
Clozapine Initiation Criteria and Monitoring Requirements
advancedclozapineANC monitoring protocolANC monitoring
→
76.
Opioid Use Disorder: Methadone vs. Buprenorphine Treatment Selection
intermediateopioid use disordermethadonebuprenorphine
→
77.
Tobacco Cessation Pharmacotherapy Selection
beginnertobacco cessationvareniclinesmoking
→
78.
Breastfeeding and Psychiatric Medications: Risk Framework
intermediatebreastfeedingsertralinerelative infant dose
→
79.
Substance Use in Pregnancy: Neonatal Abstinence Syndrome
advancedpregnancyopioid use disorderbuprenorphine
→
80.
Clozapine ANC Thresholds in Benign Ethnic Neutropenia
intermediateclozapineANC monitoring protocolbenign ethnic neutropenia
→
81.
Bupropion Contraindication in Bulimia Nervosa
beginnerbupropionseizure thresholdbulimia nervosa
→
82.
Mood Stabilizer Teratogenicity: Valproate vs Lamotrigine in Pregnancy Planning
advancedvalproatelamotrigineteratogenicity
→
83.
Alpha-1 Adrenergic Blockade and Orthostatic Hypotension with Antipsychotics
beginneralpha-1 blockadeorthostatic hypotensionchlorpromazine
→
84.
Stimulant Side Effect Management: Appetite Suppression and Weight Loss
intermediatestimulant side effectsappetite suppressionweight loss
→
85.
Naltrexone and Emergency Pain Management: Perioperative Considerations
advancednaltrexoneVivitrolperioperative management
→
86.
Trazodone Dose-Dependent Sedation vs Antidepressant Effect
intermediatetrazodoneSARIdose-dependent pharmacology
→
87.
CYP2D6 Poor Metabolizer: Nortriptyline Toxicity at Standard Doses
advancedCYP2D6poor metabolizernortriptyline
→
88.
Mirtazapine Dose-Dependent Sedation: The Noradrenergic Counterbalance
intermediatemirtazapineNaSSAdose-dependent sedation
→
89.
Buspirone Limitations: Ineffective for Panic Disorder
intermediatebuspironepanic disordergeneralized anxiety disorder
→
90.
Lithium Augmentation in Treatment-Resistant Depression
intermediatetreatment-resistant depressionlithium augmentationTRD
→
91.
Geriatric Anticholinergic Burden and Cognitive Decline
intermediateanticholinergic burdengeriatricdelirium
→
92.
ADHD Medication Management During Pregnancy
intermediateADHDpregnancystimulant medications
→
93.
Bipolar Depression on Lamotrigine — Reassessment Before Adjusting
advancedbipolar IIlamotriginebipolar depression
→
94.
SSRI Sexual Dysfunction — Differential Assessment
intermediateSSRIsexual dysfunctionfluoxetine
→
95.
Clozapine Comprehensive Monitoring
advancedclozapineREMSANC monitoring
→
96.
Tardive Dyskinesia — AIMS Assessment
intermediatetardive dyskinesiaAIMShaloperidol
→
97.
Early SSRI Response — Assessment and Suicide Risk Window
intermediateSSRIearly responsesuicidal ideation
→
98.
Valproate Hepatotoxicity — Systematic Assessment
advancedvalproatehepatotoxicityliver enzymes
→
99.
Lithium Toxicity — Assessment and Drug Interactions
advancedlithium toxicitydrug interactionsrenal function
→
100.
Anticholinergic Burden — Visual Hallucinations in Elderly
advancedanticholinergic burdenACB scalepolypharmacy
→
101.
Metabolic Lab Interpretation — Antipsychotic-Induced Metabolic Syndrome
intermediatemetabolic syndromequetiapineHbA1c
→
102.
Prolactin Elevation — Risperidone-Induced Galactorrhea
intermediateprolactinrisperidonegalactorrhea
→
103.
Venlafaxine-Induced Hypertension — Dose-Dependent Effect
intermediatevenlafaxineSNRIhypertension
→
104.
Parkinson's Disease Psychosis — Medication-Induced Assessment
advancedParkinson's diseasepramipexoledopamine agonist
→
105.
Serotonin Syndrome Differentiation from Expected SSRI Side Effects
intermediateserotonin syndromeSSRIsertraline
→
106.
QTc Prolongation — Citalopram in Elderly Patient
advancedQTc prolongationcitalopramgeriatric
→
107.
NSAID-Lithium Interaction — Acute Toxicity and Emergency Management
advancedlithium toxicityNSAID interactionibuprofen
→
108.
Lithium Nephrotoxicity — Rising Creatinine at Therapeutic Level
advancedlithiumnephrotoxicitycreatinine
→
109.
Neuroleptic Malignant Syndrome — Emergency Assessment
advancedNMSneuroleptic malignant syndromeantipsychotic
→
110.
Valproate Hyperammonemic Encephalopathy at Therapeutic Level
advancedvalproatehyperammonemiaencephalopathy
→
111.
Serotonin Syndrome — Duloxetine and Tramadol Interaction
advancedserotonin syndromeduloxetinetramadol
→
112.
Donepezil-Oxybutynin Anticholinergic Conflict in Dementia
intermediatedonepeziloxybutyninanticholinergic
→
113.
SSRI-Aspirin Bleeding Interaction — Platelet Aggregation
intermediateSSRIaspirinbleeding
→
114.
Geriatric Fall Risk — Beers Criteria and Medication Review
intermediateBeers Criteriafall riskbenzodiazepine
→
115.
Metabolic Syndrome Criteria — Olanzapine Monitoring
intermediatemetabolic syndromeolanzapineschizophrenia
→
116.
Breakthrough Mania — Subtherapeutic Lithium and Nonadherence
intermediatebipolar disorderlithiumnonadherence
→
117.
Lithium Toxicity Risk with NSAID Interaction
intermediatelithiumdrug interactionNSAID
→
118.
Augmentation Strategy for Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationaripiprazole
→
119.
CYP2D6 Poor Metabolizer and Antidepressant Selection
hardpharmacogenomicsCYP2D6nortriptyline
→
120.
Valproate Monitoring: Hepatotoxicity and Teratogenicity
intermediatevalproic acidpregnancyteratogenicity
→
121.
Carbamazepine Autoinduction and Drug Interactions
hardcarbamazepineautoinductionCYP3A4
→
122.
Renal Impairment and Lithium Dose Adjustment
hardlithiumrenal impairmentnephrotoxicity
→
123.
Augmentation Rationale in Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationSTAR*D
→
124.
Treatment Selection for Bipolar Depression
intermediatebipolar disorderbipolar depressionmood stabilizer
→
125.
PTSD First-Line vs Second-Line Treatment Rationale
intermediatePTSDtrauma-focused therapySSRI
→
126.
OCD Treatment Algorithm: ERP and Medication Integration
hardOCDERPexposure and response prevention
→
127.
Shared Decision-Making in Antipsychotic Selection
intermediateshared decision-makingantipsychoticmetabolic effects
→
128.
Comorbid Anxiety and Substance Use Treatment Prioritization
hardcomorbidityanxietysubstance use disorder
→
129.
Discontinuation Syndrome Prevention Strategies
intermediatediscontinuation syndromeSSRItapering
→
130.
Switching Antidepressant Classes and Washout Period Considerations
hardMAOIserotonin syndromewashout period
→
131.
Metabolic Monitoring Rationale for Atypical Antipsychotics
intermediatemetabolic monitoringatypical antipsychoticschizophrenia
→
132.
Treatment Planning for Comorbid ADHD and Mood Disorder
hardADHDmajor depressive disordercomorbidity
→
133.
Relapse Prevention Planning for Major Depressive Disorder
intermediaterelapse preventionmajor depressive disordermaintenance treatment
→
134.
Evaluating SSRI Partial Response at 6 Weeks
intermediateSSRIpartial responsedose optimization
→
135.
Monitoring Lithium Levels and Toxicity Recognition
hardlithiumtherapeutic drug monitoringtoxicity
→
136.
Assessing Antipsychotic Response Using Rating Scales
hardschizophreniaBPRSantipsychotic response
→
137.
Recognizing SSRI-Induced Apathy vs Residual Depression
hardSSRIemotional bluntingapathy syndrome
→
138.
Monitoring Metabolic Syndrome with Atypical Antipsychotics
intermediatemetabolic syndromeolanzapineatypical antipsychotics
→
139.
Evaluating Stimulant Response in Adult ADHD
intermediateADHDstimulantsASRS
→
140.
Recognizing Tardive Dyskinesia Early with AIMS Assessment
intermediatetardive dyskinesiaAIMShaloperidol
→
141.
Monitoring for Suicidality During Early Antidepressant Treatment
hardsuicidalityFDA black box warningSSRI
→
142.
First-Line Treatment Planning for Pediatric ADHD
intermediateADHDpediatricstimulant
→
143.
Antidepressant Selection with Hepatic Comorbidity
hardantidepressanthepatic impairmentSSRI
→
144.
Geriatric Antipsychotic Risk-Benefit Planning
hardgeriatricantipsychoticdementia
→
145.
Bipolar Maintenance Medication Planning
intermediatebipolar disorderlithiummaintenance treatment
→
146.
Collaborative Treatment Planning with Primary Care
intermediatecollaborative careprimary care integrationchronic kidney disease
→
147.
Planning for Medication Non-Adherence
intermediateschizophreniamedication adherencelong-acting injectable
→
148.
Treatment Planning for Comorbid Chronic Pain and Depression
hardchronic paindepressionSNRI
→
149.
Evaluating Clozapine Treatment Response and Monitoring
hardclozapinetreatment-resistant schizophreniaBPRS
→
150.
Assessing Benzodiazepine Taper Progress
intermediatebenzodiazepinetaperwithdrawal
→
151.
Evaluating Mood Stabilizer in Bipolar Maintenance
hardvalproatebipolar Imaintenance treatment
→
152.
Evaluating Cognitive Side Effects of Medications
hardtopiramatequetiapinecognitive side effects
→
153.
Assessing Weight Gain Management with Antipsychotics
hardolanzapinemetabolic syndromeweight gain
→
154.
Evaluating Smoking Cessation Pharmacotherapy Outcomes
hardvareniclinesmoking cessationschizophrenia
→
155.
Monitoring Thyroid Function During Lithium Treatment
intermediatelithiumhypothyroidismTSH
→
156.
Evaluating Antidepressant Augmentation Effectiveness
intermediatearipiprazoleaugmentationakathisia
→
157.
Trazodone Mechanism and Dual-Use Rationale
intermediatetrazodoneSARIinsomnia
→
158.
Prazosin Mechanism for PTSD Nightmares
intermediateprazosinPTSDnightmares
→
159.
Gabapentin Off-Label Use and Mechanism
intermediategabapentinalpha-2-deltacalcium channel
→
160.
Aripiprazole Partial Agonist Mechanism
intermediatearipiprazolepartial agonistD2 receptor
→
161.
Mirtazapine Receptor Profile and Clinical Implications
intermediatemirtazapineNaSSAreceptor profile
→
162.
Fluvoxamine Sigma-1 Receptor and Drug Interactions
hardfluvoxamineCYP1A2drug interactions
→
163.
Esketamine (Spravato) Mechanism and Administration
hardesketamineSpravatoNMDA
→
164.
Pimavanserin for Parkinson's Disease Psychosis
hardpimavanserin5-HT2AParkinson's disease psychosis
→
165.
Brexanolone and Neurosteroid Mechanism
hardbrexanoloneZulressoallopregnanolone
→
166.
Deutetrabenazine for Tardive Dyskinesia Mechanism
harddeutetrabenazineVMAT2tardive dyskinesia
→
167.
Vilazodone and Vortioxetine Multimodal Mechanism
hardvortioxetinemultimodalcognitive symptoms
→
168.
Dextromethorphan-Bupropion (Auvelity) Mechanism
harddextromethorphan-bupropionAuvelityNMDA antagonist
→
169.
Clozapine Initiation Criteria and Monitoring
hardclozapinetreatment-resistant schizophreniaREMS
→
170.
Treatment Planning for Refractory OCD
hardOCDtreatment-resistantantipsychotic augmentation
→
171.
Esketamine Treatment Protocol Planning
hardesketamineSpravatotreatment-resistant depression
→
172.
Geriatric Depression Augmentation Strategy
hardgeriatric depressionaugmentationaripiprazole
→
173.
Pharmacogenomic-Guided Treatment Planning
hardpharmacogenomicsCYP2D6CYP2C19
→
174.
Long-Acting Injectable Antipsychotic Planning
hardlong-acting injectablerisperidonepaliperidone
→
175.
Treatment-Resistant Bipolar Depression Planning
hardbipolar depressiontreatment-resistantquetiapine
→
176.
Perinatal Depression Treatment Planning
hardperinatal depressionpregnancysertraline
→
177.
Differentiating Serotonin Syndrome from NMS
hardserotonin syndromeneuroleptic malignant syndromedrug interaction
→
178.
Evaluating Geriatric Anxiety Treatment Response
hardgeriatricanxietyGAD-7
→
179.
Evaluating Prolactin Elevation with Antipsychotics
hardprolactinrisperidonehyperprolactinemia
→
180.
Assessing Rebound Psychosis After Antipsychotic Discontinuation
hardsupersensitivity psychosisantipsychotic discontinuationolanzapine
→
181.
Monitoring Hepatic Function During Valproate Treatment
intermediatevalproatehepatotoxicityliver function tests
→
182.
Evaluating Alpha-2 Agonist Response for ADHD
hardguanfacineADHDalpha-2 agonist
→
183.
Assessing Treatment-Emergent Mania
hardtreatment-emergent maniabipolar disorderfluoxetine
→
184.
Monitoring Renal Function During Long-Term Lithium
hardlithiumrenal functionchronic kidney disease
→
185.
Concurrent Buprenorphine and Antidepressant Therapy Planning
hardbuprenorphineantidepressantopioid use disorder
→
186.
Treatment Planning for Catatonia with Lorazepam Challenge
hardcatatonialorazepam challengebenzodiazepines
→
187.
Antidepressant Selection in a Patient with Cardiac Disease
hardcardiacpost-MI depressionsertraline
→
188.
Treatment Planning for Comorbid Epilepsy and Depression
hardepilepsydepressionlamotrigine
→
189.
Treatment Planning for Late-Life Psychosis
hardlate-life psychosisParkinsonismquetiapine
→
190.
Prevention of Serotonin Discontinuation Syndrome
harddiscontinuation syndromeparoxetinetaper strategy
→
191.
Antipsychotic Selection in a Patient with Diabetes
intermediateschizophreniadiabetesmetabolic syndrome
→
192.
Treatment Planning for Pediatric OCD
hardpediatric OCDfluvoxamineCBT
→
193.
Treatment Planning for Treatment-Resistant Anxiety
hardtreatment-resistant anxietyGADbuspirone
→
194.
Planning Cross-Taper Between Antipsychotics
hardcross-taperantipsychotic switchingolanzapine
→
195.
Treatment Planning for Substance-Induced Psychosis
intermediatesubstance-induced psychosismethamphetaminebenzodiazepines
→
196.
Treatment Planning for Comorbid Autism and Aggression
intermediateautismaggressionrisperidone
→
197.
Evaluating Treatment Response in First-Episode Psychosis
hardfirst-episode psychosisrisperidonePANSS
→
198.
Evaluating SNRI Efficacy for Comorbid Pain and Depression
hardduloxetineSNRIfibromyalgia
→
199.
Evaluating for Medication-Induced QTc Prolongation
hardQTc prolongationziprasidoneondansetron
→
200.
Evaluating Prazosin Efficacy for Trauma-Related Nightmares
hardprazosinPTSDnightmares
→
201.
Evaluating Methylphenidate vs Amphetamine Response
hardADHDmethylphenidateamphetamine
→
202.
Evaluating Strategies for Medication-Induced Weight Gain
hardolanzapineweight gainmetabolic syndrome
→
203.
Evaluating Treatment Adherence with LAI Antipsychotics
hardLAIaripiprazole lauroxiladherence
→
204.
Evaluating for Emerging Diabetes During Antipsychotic Treatment
harddiabetesquetiapinemetabolic monitoring
→
205.
Evaluating Buspirone Augmentation for Anxiety
hardbuspironeaugmentationgeneralized anxiety disorder
→
206.
Evaluating Gabapentinoid Efficacy for Neuropathic Pain in Psychiatric Patients
hardpregabalinneuropathic painrenal impairment
→
207.
Valproate-Lamotrigine Glucuronidation Interaction
hardvalproatelamotrigineUGT1A4
→
208.
Fluvoxamine-Clozapine CYP1A2 Inhibition
hardfluvoxamineclozapineCYP1A2
→
209.
Carbamazepine Enzyme Induction and Oral Contraceptive Failure
hardcarbamazepineoral contraceptivesCYP3A4
→
210.
Lithium-NSAID Renal Interaction Mechanism
hardlithiumNSAIDibuprofen
→
211.
Serotonin Syndrome Risk with Tramadol and SSRI Combination
hardtramadolSSRIsertraline
→
212.
Methadone QTc Prolongation and CYP3A4 Inhibitor Risk
hardmethadoneQTc prolongationCYP3A4
→
213.
Grapefruit Juice CYP3A4 Interaction with Psychiatric Medications
hardgrapefruit juicebuspironeCYP3A4
→
214.
Warfarin-SSRI Bleeding Risk Interaction
hardwarfarinfluoxetineSSRI
→
215.
Smoking Cessation Effect on Clozapine Metabolism
hardclozapinesmoking cessationCYP1A2
→
216.
Levothyroxine Absorption and Psychiatric Medication Timing
intermediatelevothyroxinecalciumiron
→
217.
Disulfiram-Alcohol Reaction Mechanism
harddisulfiramalcohol use disorderaldehyde dehydrogenase
→
218.
Buprenorphine Partial Agonist Ceiling Effect
hardbuprenorphinepartial agonistceiling effect
→
219.
Medication Management Planning for First-Episode Psychosis
hardfirst-episode psychosisantipsychoticssecond-generation antipsychotics
→
220.
Planning for Acute Agitation in Emergency Psychiatric Settings
hardacute agitationemergency psychiatryintramuscular antipsychotics
→
221.
Treatment Planning for Treatment-Resistant Schizophrenia
hardtreatment-resistant schizophreniaclozapineREMS
→
222.
Treatment Planning for Anorexia Nervosa with Comorbid Depression
hardanorexia nervosadepressioneating disorders
→
223.
Planning Medication Management During Breastfeeding
hardpostpartum depressionbreastfeedinglactation
→
224.
Treatment Planning for Acute Mania
hardbipolar disorderacute manialamotrigine
→
225.
Planning Treatment for Comorbid Fibromyalgia and Depression
hardfibromyalgiadepressionduloxetine
→
226.
Planning Medication Management for Chronic PTSD
hardPTSDsertralineprazosin
→
227.
Treatment Planning for Tardive Dyskinesia Management
hardtardive dyskinesiaVMAT2 inhibitorvalbenazine
→
228.
Evaluating Anticonvulsant Mood Stabilizer Blood Levels
hardvalproic acidtherapeutic drug monitoringketogenic diet
→
229.
Evaluating the Effect of Pregnancy on Psychiatric Medication Metabolism
hardpregnancysertralinepharmacokinetics
→
230.
Evaluating for Antidepressant Poop-Out (Tachyphylaxis)
hardtachyphylaxisantidepressant poop-outescitalopram
→
231.
Evaluating Cognitive Effects of Benzodiazepines in Elderly
hardbenzodiazepineslorazepamelderly
→
232.
Evaluating Impact of Comorbid Medical Conditions on Psychiatric Treatment
hardchronic kidney diseasevenlafaxinerenal clearance
→
233.
Planning Medication Management for Serotonin Syndrome Prevention
hardserotonin syndromedrug interactionsSNRI
→
234.
Treatment Planning for ADHD in College Students
hardADHDstimulantscollege students
→
235.
Planning Withdrawal Management for Polysubstance Use
hardpolysubstance withdrawalalcohol withdrawalbenzodiazepine withdrawal
→
236.
Planning Pharmacotherapy for Postpartum Psychosis
hardpostpartum psychosislithiumbipolar disorder
→
237.
Planning Treatment for Body Dysmorphic Disorder
hardbody dysmorphic disorderSSRICBT
→
238.
Treatment Planning for Co-Occurring Chronic Illness and Depression
harddiabetesneuropathic painduloxetine
→
239.
Lamotrigine Titration and Stevens-Johnson Syndrome Risk
intermediatelamotrigineStevens-Johnson syndromemood stabilizer
→
240.
SSRI Discontinuation Syndrome Identification
intermediateSSRIdiscontinuation syndromeparoxetine
→
241.
Antipsychotic Metabolic Syndrome Monitoring
intermediateolanzapinemetabolic syndromeantipsychotic
→
242.
Clozapine Monitoring Requirements and Agranulocytosis
intermediateclozapineREMSagranulocytosis
→
243.
Hepatic Impairment and Psychotropic Dose Adjustment
hardhepatic impairmentcirrhosisantidepressant
→
244.
QTc Prolongation Risk in Antipsychotic Selection
hardQTc prolongationantipsychoticaripiprazole
→

Other AANPCB knowledge areas

🧬 Scientific Foundations⚡ Nonpharmacological Therapies🗣️ Psychotherapies🔍 Assessment & Diagnosis📋 Care Practices📌 Professional Role
← AANPCB Board Prep